ライフサイエンスコーパス: cirrhotic

1 ced), and cirrhosis status (noncirrhotic vs. cirrhotic).

2 invasion; 68% of HBV versus 89% of HCV were cirrhotic.

3 OL and systemic inflammation compared to non-cirrhotics.

4 fibrosis (noncirrhotic, 63.3% versus 41.9%; cirrhotic, 38.1% versus 21.7%).

5 278 cirrhotics [39% hepatic encephalopathy (HE), 31%DM] unde

6 A total of 111 patients (61 cirrhotic; 50 postliver transplants) with HCV genotype 4

7 187 subjects (40 controls, 147 cirrhotic; 87 with HE) underwent systemic inflammatory a

8 84 patients [90.5% males, 89.2% cirrhotics, 89.2% nodular HCC, median age 63 (34-84) yea

9 xaminations performed on 42 males, including cirrhotic alcoholics (n = 13), non-cirrhotic alcoholics

10 including cirrhotic alcoholics (n = 13), non-cirrhotic alcoholics (n = 15), non-alcoholic controls (n

11 To examine this issue, hepatocytes from cirrhotic and age-matched control rats were isolated, ch

12 c FGF19 mRNA expression was increased in non-cirrhotic and cirrhotic tissues (9-fold,p = 0.01; 69-fol

13 Cells from cirrhotic and control livers engrafted equally well, but

14 estigated the differences of angiogenesis in cirrhotic and non-cirrhotic PHT with special emphasis on

15 summary, statins caused contrary effects in cirrhotic and non-cirrhotic portal hypertension.

16 Cirrhotic and noncirrhotic liver tissues were obtained f

17 ce daily for 12 weeks in genotype 1-infected cirrhotic and noncirrhotic patients who had failed treat

18 achieved high SVR12 rates in treatment-naive cirrhotic and noncirrhotic patients with genotype 1, 4,

19 Cirrhotic and noncirrhotic subjects were matched 1:5 on

20 are up-regulated, in mesentery and liver, in cirrhotic and precirrhotic portal hypertensive rats and

21 e review differences and similarities in the cirrhotic and precirrhotic stages of NAFLD and alcoholic

22 s with chronic hepatitis C: On the one side, cirrhotic and tumor fragments were moderately and highly

23 (80%) were HCV treatment-naive, 14 (6%) were cirrhotic, and 108 (46%) were African American.

24 gible articles were stratified into general, cirrhotic, and populations coinfected with human immunod

25 atory and systemic inflammatory responses in cirrhotic animals.

26 Although the factors involved in cirrhotic ascites have been studied for a century, a num

27 hway, a less differentiated phenotype, and a cirrhotic background.

28 In this study, cirrhotic bile duct ligated (BDL) rats with PH were trea

29 Cirrhotic (bile duct ligation/BDL; CCl4 intoxication) an

30 Cirrhotic BM showed an inverse correlation between clust

31 Consistent with these findings, cirrhotic, but not normal, human livers contained GAPDH

32 s.c. or intrahepatic injection in normal and cirrhotic (carbon tetrachloride-induced) mice.

33 We proposed that features of cirrhotic cardiomyopathy are present in infants with cir

34 Overall, features of cirrhotic cardiomyopathy were observed in most infants (

35 Cirrhotic cardiomyopathy, a condition characterized by i

36 cular response to stress, a condition termed cirrhotic cardiomyopathy.

37 GF cirrhotic mice developed similar cirrhotic changes to conventional mice after 4 extra wee

38 can last for one year after treatment in non-cirrhotic CHB patients without a virological breakthroug

39 participants were aged 18-70 years with non-cirrhotic, chronic HCV genotype 4 infection (documented

40 define gut-brain axis alterations in elderly cirrhotics compared to non-cirrhotic individuals based o

41 Liver cancer and cirrhotic complications are rare.

42 s induced in the liver under cholestatic and cirrhotic conditions.

43 mean FIB-4 score >5.88-and time to onset of cirrhotic decompensation in electronic medical records.

44 Cirrhotics demonstrated significant changes on MR spectr

45 ved in 22 patients including 2 fatalities in cirrhotic diabetes patients.

46 Cirrhotic explant livers showed robust HLA-G expression

47 he stromal compartment around 176 nodules in cirrhotic explants was examined.

48 is strongly associated with both tumoral and cirrhotic factors and accurately predicts long-term surv

49 acteristic curve, 0.753) for differentiating cirrhotic from noncirrhotic livers (P = .038 and .003, r

50 routine CT images accurately differentiated cirrhotic from noncirrhotic livers and was highly reprod

51 Accuracy for differentiating cirrhotic from noncirrhotic livers was assessed by area

52 mpared between the OPV patient group and the cirrhotic group and also among the conditions associated

53 al population, 0.26 (95% CI, .18-.74) in the cirrhotic group, and 0.21 (.10-.45) in the coinfected gr

54 Cirrhotics had a prolonged QTc interval, a Q wave, abnor

55 Cirrhotics had in median 27 times more bacterial DNA of

56 Furthermore, skeletal muscle from cirrhotics had increased expression of myostatin, a know

57 Cytokine profiles did not distinguish cirrhotic HBV patients with and without HCC (AUC 0.503)

58 In cirrhotic HCV GT1- or GT3-infected patients, ABT-493 plu

59 From observational studies among compensated cirrhotic hepatitis C patients treated with interferon-c

60 y information on the chemical composition of cirrhotic hepatocytes and fibrotic septa in cirrhosis.

61 F revealed enrichment in calcium compared to cirrhotic hepatocytes.

62 Cirrhotic HIV/HCV-coinfected patients enrolled in the Fr

63 associated with a high virologic efficacy in cirrhotic HIV/HCV-coinfected patients.

64 Of 137 cirrhotic hospitalized patients, 121 cirrhotic patients

65 ied in difficult-to-treat null responder and cirrhotic human immunodeficiency virus (HIV)-coinfected

66 vels and beta-catenin activation in fibrotic/cirrhotic human liver tissues.

67 s critical cell subset may contribute to the cirrhotic immunodeficiency state and heightened risk of

68 ations in elderly cirrhotics compared to non-cirrhotic individuals based on presence of cirrhosis and

69 ocellular carcinoma (HCC), especially in non-cirrhotic individuals.

70 e strategy for well-compensated HCV-infected cirrhotics listed for liver transplantation with hepatoc

71 ed was restricted to well-compensated HCV(+) cirrhotics listed for liver transplantation with hepatoc

72 of patients with HCC is diagnosed in the non-cirrhotic liver (NCL).

73 liver disease and 13.3% in patients with non-cirrhotic liver disease (adjusted RR of 1.49 95% confide

74 ts underwent CRC surgery: 369 (0.9%) had non-cirrhotic liver disease and 158 (0.4%) had liver cirrhos

75 zed them into two cohorts: patients with non-cirrhotic liver disease and patients with liver cirrhosi

76 In a cirrhotic liver environment, cells could differentiate i

77 hate phosphatase 1 in normal human liver and cirrhotic liver from patients with alcohol-related liver

78 r in controls between different areas of the cirrhotic liver or between liver and serum.

79 ver resection, 168 paired non-tumor adjacent cirrhotic liver samples, and 10 non-tumor liver tissues

80 was determined through the analysis of human cirrhotic liver specimens, widely accepted in vivo anima

81 study, we have addressed the composition of cirrhotic liver tissue by combining synchrotron Fourier

82 SDF-1alpha expression with fibrotic septa in cirrhotic liver tissues as well as with desmoplastic reg

83 erved increased levels of CPEB1 and CPEB4 in cirrhotic liver tissues from patients, compared with con

84 2500 Hz (22.8% in healthy liver vs 24.5% in cirrhotic liver) that was not significant when the Bonfe

85 o the most common bacteria translocated into cirrhotic liver, although there were no statistically si

86 liver function after transplantation into a cirrhotic liver, and co-localized with the pericyte mark

87 In cirrhotic liver, COL15A1-expressing PMFs adopted a periv

88 In the perfused TAA and BDL cirrhotic liver, INT-747 improved endothelial vasorelaxa

89 of carcinogenesis, as 90% of HCCs arise in a cirrhotic liver.

90 from nonenhanced thick-section CT images in cirrhotic livers (3.16; 56 livers) were significantly hi

91 short heterodimer partner were increased in cirrhotic livers (9-fold, p < 0.001; 3.5-fold,p = 0.007;

92 cal between healthy (range, 26.0%-80.0%) and cirrhotic livers (range, 26.7%-81.2%) for all frequency

93 RT6 was significantly down-regulated in both cirrhotic livers and cancer.

94 oteins were highly expressed in DRs of human cirrhotic livers and cholangiocarcinoma.

95 n 19-labeled ductular reaction (DR) in human cirrhotic livers and in an experimental cirrhosis induce

96 Cirrhotic livers exhibit intrahepatic endothelial dysfun

97 found that ductular reaction cells in human cirrhotic livers express hepatocyte nuclear factor 1 hom

98 homolog, CcnE2, was induced in fibrotic and cirrhotic livers from human patients with different etio

99 Patients with cirrhotic livers had significantly increased levels of v

100 Repair of cirrhotic livers occurs, in part, by repopulation with h

101 cytes recovered from progressively worsening cirrhotic livers suggest that hepatocytes from irreversi

102 ysiological features of HCCs, which occur in cirrhotic livers that show pronounced necroinflammation,

103 rimary human liver cancers and in normal and cirrhotic livers using microarray analysis.

104 c proteins, whereas hepatocytes derived from cirrhotic livers with decompensated function failed to m

105 For cirrhotic livers, a significantly lower total perfusion,

106 In cirrhotic livers, activation of the XBP1-Hrd1 arm of ER

107 lar carcinomas (HCCs) develop in fibrotic or cirrhotic livers, suggesting an important role of liver

108 By contrast, in intrahepatic xenografts in cirrhotic livers, tumors were dominated by epithelial tr

109 on of lysosomal cathepsin D were observed in cirrhotic livers.

110 e the original human CCAs when injected into cirrhotic livers.

111 ce, is a major mechanism for repopulation of cirrhotic livers.

112 r patients with hepatocellular carcinoma and cirrhotic livers.

113 mily, is accumulated in hepatocytes of human cirrhotic livers.

114 in hepatic stellate cell (HSC) apoptosis in cirrhotic livers.

115 nical utility in differentiating healthy and cirrhotic livers.

116 ocytes and has been detected in fibrotic and cirrhotic livers.

117 erences in multiple areas of control non-HCC cirrhotic livers.

118 containing HCC compared with control non-HCC cirrhotic livers.

119 investigated the roles of autophagy in human cirrhotic livers.

120 c that decreases lipopolysaccharide (LPS) in cirrhotics, may decrease the elevated levels of microbia

121 GF cirrhotic mice developed similar cirrhotic changes to co

122 GF cirrhotic mice exhibited higher ammonia, compared to GF

123 However, conventional cirrhotic mice had intestinal dysbiosis as well as syste

124 In both cirrhotic models, FXR expression was decreased.

125 n 2 activation were consistently reversed in cirrhotic muscle (P < 0.01).

126 acellular concentrations similar to those in cirrhotic muscle.

127 s in tissues from non-cirrhotic (n = 24) and cirrhotic (n = 21) patients along with control tissues (

128 response to cholestasis in tissues from non-cirrhotic (n = 24) and cirrhotic (n = 21) patients along

129 ally identifiable patterns: "complex" around cirrhotic nodules (CN), "attenuated" around dysplastic n

130 Accurate characterization of cirrhotic nodules and early diagnosis of hepatocellular

131 , that thickness of fibrous septa separating cirrhotic nodules and small size of cirrhotic nodules co

132 parating cirrhotic nodules and small size of cirrhotic nodules correlated independently with portal p

133 A high heterogeneity was observed between cirrhotic nodules in their content in sugars and iron.

134 promoter mutations in the transformation of cirrhotic nodules into hepatocellular carcinoma (HCC).

135 Hepatocytes within cirrhotic nodules were characterized by high content in

136 d to profile miRNA expression in 55 samples (cirrhotic nodules; CNs), LGDNs, HGDNs, early HCCs, and s

137 lls were more prominent in fibrotic areas of cirrhotic Nogo-B KO livers.

138 Livers from cirrhotic Nogo-B KO mice showed significantly reduced fi

139 ical centres in the USA in patients with non-cirrhotic, non-alcoholic steatohepatitis to assess treat

140 chemistry in 91% of HH-HCC, 0% of HH-related cirrhotic or dysplastic nodules and 79% of mixed-aetiolo

141 Cirrhotic outpatients with/without DM underwent stool an

142 gene expression was higher in HCC than both cirrhotic paired tissue and normal tissue.

143 uct ligation/BDL; CCl4 intoxication) and non-cirrhotic (partial portal vein ligation/PPVL) rats recei

144 Of 137 cirrhotic hospitalized patients, 121 cirrhotic patients (88.3 %) with AKI-prone conditions we

145 treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive

146 tive options for hepatocellular carcinoma in cirrhotic patients (HCC-cirr).

147 tis C virus (HCV) patients (n = 20), group 3 cirrhotic patients (LC) (n = 20), and HCC group (n = 20)

148 small intestine was significantly higher in cirrhotic patients (median 1.27 metres (m)/hour, range 0

149 K NAFLD cohort, in the overall cohort of non-cirrhotic patients (n = 913, 41 with HCC) the T allele r

150 NT-proBNP changes at the end of drainage in cirrhotic patients (P < 0.01).

151 Analysis was limited to cirrhotic patients 18 years old or older, with serum cre

152 We prospectively enrolled cirrhotic patients admitted at the King Chulalongkorn Me

153 as a prospective evaluation in two series of cirrhotic patients admitted with infection or developing

154 During the period, 207 cirrhotic patients among 525 LT were studied.

155 ith an MRR of 0.64 (95% CI, 0.40-1.01) among cirrhotic patients and 2.33 (1.47-3.67) compared with th

156 The study included 41,076 cirrhotic patients and 204,244 noncirrhotic controls fro

157 he proteins in plasma samples of control and cirrhotic patients and by visualizing the separated prot

158 icant difference between the total cohort of cirrhotic patients and controls.

159 of ascitic fluid; it has a high incidence in cirrhotic patients and it is associated with high mortal

160 sR were increased in splanchnic vessels from cirrhotic patients and rats compared with healthy contro

161 sma OPN in the diagnosis of HCC in alcoholic cirrhotic patients and to investigate whether increased

162 Lactulose therapy was effective for cirrhotic patients as primary prophylaxis to prevent ove

163 y, plasma FA lipidome was investigated in 51 cirrhotic patients before liver transplantation and in 9

164 ma samples and skeletal muscle biopsies from cirrhotic patients compared with healthy controls.

165 tly higher active TB rate was maintained for cirrhotic patients compared with their noncirrhotic coun

166 s of HCV therapy due to adverse events among cirrhotic patients could partially explain the differenc

167 A total of 957 of 41,076 (2.32%) cirrhotic patients developed TB, yielding a rate that wa

168 However, the risk of TB in cirrhotic patients has rarely been investigated.

169 Cirrhotic patients have a greater risk of TB than noncir

170 We enrolled cirrhotic patients hospitalized with the first presentat

171 gM(+) B cells were markedly less frequent in cirrhotic patients independent of HCV infection.

172 post-liver transplantation (LT) mortality in cirrhotic patients is unanswered.

173 phase 2, double-blind, controlled study, 22 cirrhotic patients referred for HVPG measurement were in

174 Two cirrhotic patients relapsed and 2 discontinued treatment

175 Hepatitis C Virus (HCV) cirrhotic patients showed coinduction of Collagen-I and

176 ression of CD95(Fas) in CD27(+) B-cells from cirrhotic patients that was inversely correlated with pe

177 In cirrhotic patients transplanted with large splenorenal s

178 Information on the outcome of cirrhotic patients undergoing a transplant for HCC and w

179 Adult cirrhotic patients undergoing first-time liver transplan

180 Cirrhotic patients undergoing first-time liver transplan

181 Among 336 cirrhotic patients undergoing LT between 2000 and 2011,

182 thin the splanchnic circulation of alcoholic cirrhotic patients undergoing TIPSS insertion for varice

183 Forty-six cirrhotic patients were included with hepatitis C (87%)

184 While memory B-cells from cirrhotic patients were resistant to Fas-mediated apopto

185 The outcomes and optimal management of cirrhotic patients who develop cryptococcosis before tra

186 Among cirrhotic patients who underwent evaluation for HCC with

187 Conclusion ELF is not uncommon in cirrhotic patients with a MELD score of 12 or less who u

188 sed to provide prognostic information in HBV cirrhotic patients with ACLF.

189 890 HBV associated cirrhotic patients with acute decompensation (AD) were e

190 ed corticosteroid insufficiency is common in cirrhotic patients with acute gastroesophageal variceal

191 rospective cohort study was conducted on 235 cirrhotic patients with acute peptic ulcer hemorrhage wh

192 r the early detection of AKI in hospitalized cirrhotic patients with AKI-prone conditions; however, i

193 Cirrhotic patients with ascites are prone to develop var

194 diseases for 30-day and 90-day mortality of cirrhotic patients with ascites were 1.81 (1.54-2.11) an

195 Of the total 4,576 cirrhotic patients with ascites, 1,294 (28.2%) were diag

196 al Health Insurance Program, to enroll 4,576 cirrhotic patients with ascites, who were discharged fro

197 ses increased 30-day and 90-day mortality of cirrhotic patients with ascites.

198 ajor infectious diseases on the mortality of cirrhotic patients with ascites.

199 y from 12 to 8 weeks in treatment naive, non-cirrhotic patients with baseline HCV RNA levels <6 milli

200 Finally, in a combined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic

201 coexisting DM and CKD increase mortality in cirrhotic patients with EVB remains unclear.

202 Among the cirrhotic patients with EVB, all-cause mortality at 42-d

203 Records from 861 cirrhotic patients with HCC consecutively listed for eit

204 ight be exploited to improve the outcomes of cirrhotic patients with HCCs.

205 Cirrhotic patients with HCV who achieve SVR should there

206 eat analysis of overall survival (ITT-OS) of cirrhotic patients with hepatocellular carcinoma (HCC) l

207 e safety profile was acceptable, even though cirrhotic patients with low albuminemia and platelets sh

208 Resting-state fMRI was administered to 33 cirrhotic patients with MHE and 43 cirrhotic patients wi

209 were to assess whether (1) MMN is altered in cirrhotic patients with MHE, compared to those without M

210 However, cirrhotic patients with null-responses to EBV peptides h

211 ined liver-kidney transplantation (CLKT) for cirrhotic patients with renal failure (RF) is controvers

212 study was undertaken to compare outcomes of cirrhotic patients with RF who received either liver tra

213 Cirrhotic patients with RF, in particular with hepatoren

214 These findings were most pronounced in cirrhotic patients with systemic inflammation but fell s

215 Peripheral blood was obtained from 22 cirrhotic patients with systemic inflammation, 13 cirrho

216 er transplantation (LT) in the management of cirrhotic patients with tumors exhibiting intrahepatic b

217 Infections in cirrhotic patients with upper gastrointestinal bleeding

218 red to 33 cirrhotic patients with MHE and 43 cirrhotic patients without MHE (NMHE).

219 otic patients with systemic inflammation, 13 cirrhotic patients without systemic inflammation and 14

220 tistical significance when comparing against cirrhotic patients without systemic inflammation.

221 V infection six months post-therapy (relapse-cirrhotic patients).

222 Among cirrhotic patients, 46% never had hepatic imaging.

223 ), 92.6% (95% CI, 75.7%-99.1%; n = 25/27) in cirrhotic patients, 94.6% (95% CI, 81.8%-99.3%; n = 35/3

224 by co-culturing these cells with plasma from cirrhotic patients, a sensitivity partially mediated by

225 was associated with a reduction in MR among cirrhotic patients, but the MR remained higher than the

226 ontent was lower in the skeletal muscle from cirrhotic patients, hyperammonaemic portacaval anastomos

227 al spectra of overt EH and the complexity of cirrhotic patients, it is very difficult to perform qual

228 ul diagnostic biomarker for HCC in alcoholic cirrhotic patients, particularly in the early stages.

229 In cirrhotic patients, pre-LT BNP serum level was an indepe

230 The FA pattern was markedly altered in cirrhotic patients, who showed, compared with healthy co

231 infections and reduced rebleeding events in cirrhotic patients.

232 r diagnosing AKI and its prognostic value in cirrhotic patients.

233 a mechanism by which sarcopenia develops in cirrhotic patients.

234 was found to improve its predictive value in cirrhotic patients.

235 nt should be performed systematically in all cirrhotic patients.

236 transplant exception points and priority for cirrhotic patients.

237 ence of metabolic bone disorders among viral cirrhotic patients.

238 hen compared with non-responders and relapse-cirrhotic patients.

239 ease (4.06 +/- 0.72 kPa/year; P < 0.0001) in cirrhotic patients.

240 erichia coli in undiluted ascitic fluid from cirrhotic patients.

241 of uNGAL for diagnosing AKI in hospitalized cirrhotic patients; and (2) to explore the association o

242 known to increase mortality in hospitalized cirrhotic patients; therefore early identification is ut

243 TRbeta1 and miR-181a was also found in human cirrhotic peritumoral tissue, compared to normal liver.

244 ther evaluation as a potential treatment for cirrhotic PH.

245 erences of angiogenesis in cirrhotic and non-cirrhotic PHT with special emphasis on the canonical (Sh

246 d the activation of healthy donor B cells by cirrhotic plasma, suggesting a role for bacterial transl

247 ignaling pathways in different rat models of cirrhotic portal hypertension (PHT).

248 caused contrary effects in cirrhotic and non-cirrhotic portal hypertension.

249 intrahepatic portosystemic shunt (TIPS) for cirrhotic portal hypertension.

250 anaemia and treatment discontinuation in non-cirrhotic previously untreated and previously treated pa

251 Among cirrhotic prior null responders, SVR12 was achieved by 9

252 of a substantial degree of regression in the cirrhotic process, with the possible prevention of hepat

253 travenous injection of C/EBPalpha-saRNA in a cirrhotic rat model with multifocal liver tumors increas

254 change in liver fibrosis was observed in BDL-cirrhotic rats but an increase in the eNOS pathway.

255 nificantly change arterial pressure in CCl4 -cirrhotic rats but decreased it significantly in BDL-cir

256 Cirrhotic rats exposed to CIH exhibited an attenuated va

257 Two groups of BDL and cirrhotic rats induced by carbon tetrachloride (CCl(4) )

258 sis were evaluated in CCl4 and thioacetamide-cirrhotic rats treated with RVXB (20 mg/kg/day) or its v

259 naling pathway were measured in CCl4 and BDL cirrhotic rats treated with terutroban (30 mg/kg/day) or

260 decreased hepatic resistance, which in CCl4 -cirrhotic rats was linked to decreased hepatic fibrosis,

261 Normal and cirrhotic rats were exposed for 14 days to repetitive cy

262 NASH cirrhotic rats with hyperleptinemia were induced in Zuck

263 In cirrhotic rats, bowel decontamination with antibiotics e

264 In a group of cirrhotic rats, in vivo systemic and hepatic hemodynamic

265 In CCl4 -cirrhotic rats, terutroban reduced liver fibrosis and de

266 ates intrahepatic endothelial dysfunction in cirrhotic rats, which is associated with increased oxida

267 nesis, hepatic angiogenesis, and fibrosis in cirrhotic rats.

268 200mg/kg, thrice-weekly for 8 weeks)-induced cirrhotic rats.

269 rosis (LF), liver microthrombosis, and PH in cirrhotic rats.

270 c rats but decreased it significantly in BDL-cirrhotic rats.

271 stance (IHR) and portal hypertension in NASH cirrhotic rats.

272 , intrahepatic angiogenesis, and fibrosis in cirrhotic rats.

273 increase IHR and portal hypertension in NASH cirrhotic rats.

274 A transcriptome meta-analysis of >500 human cirrhotics revealed global regulatory gene modules drivi

275 icted functions were significantly higher in cirrhotic saliva.

276 highly expressed in activated HSCs in human cirrhotic samples.

277 odules (LGDNs and HGDNs, respectively), in a cirrhotic setting.

278 a have been shown to affect precirrhotic and cirrhotic stages of liver diseases, which could lead to

279 Cirrhotic stool microbiota demonstrated a significantly

280 he EVR group (n = 76) was younger, had fewer cirrhotic subjects, had a higher proportion with the IL2

281 havioral decline or inflamm-aging in elderly cirrhotic subjects.

282 In livers from CCl4 and BDL-cirrhotic terutroban-treated rats, endothelial dysfuncti

283 In vivo, murine and human cirrhotic tissue displayed increased TANGO1 messenger RN

284 xpression was increased in non-cirrhotic and cirrhotic tissues (9-fold,p = 0.01; 69-fold,p < 0.0001,

285 e measured from both focal liver lesions and cirrhotic tissues (from the 5 HCC patients).

286 ession pattern of 186 genes in corresponding cirrhotic tissues increased its prognostic accuracy.

287 kappaB increased dramatically from normal to cirrhotic to HCC tissues from human patients.

288 r disease and renal impairment are common in cirrhotic transplant candidates.

289 th respect to the survival of non-alcoholic, cirrhotic transplant patients (3 year survival: 66.8% wi

290 alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-naive, patients with HCV.

291 tratified by HCV genotype [1a vs 1b]) 60 non-cirrhotic, treatment-naive patients to receive sofosbuvi

292 GF and conventional C57BL/6 mice were made cirrhotic using CCl4 gavage.

293 CD14 expression percentage in cirrhotics was significantly higher than in the autopsy

294 s with HCV-related HCC, and non-HCV-infected cirrhotics were assessed for B-cell phenotype by flow cy

295 Circulating B cells in cirrhotics were hyporesponsive to CD40/TLR9 activation,

296 Cirrhotics were impaired on non-amnestic and selected am

297 nd colonic mucosal microbiome are altered in cirrhotics who get hospitalized with independent predict

298 In compensated cirrhotics with early hepatocellular carcinoma (HCC-cirr

299 ust frailty index scores (<20th percentile), cirrhotics with poor frailty index scores (>80th percent

300 and hyperammonemia compared to controls and cirrhotics without HE.